Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR

The DNA-damage response in human biology and disease

Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092 · see citing works

DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation

Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466 · see citing works

Patterns of somatic mutation in human cancer genomes

Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,062 · see citing works

Somatic mutations affect key pathways in lung adenocarcinoma

Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · see citing works

An Oncogene-Induced DNA Damage Model for Cancer Development

Halazonetis, T. D., Gorgoulis, V. G., & Bartek, J. (2008) · Science · doi:10.1126/science.1140735 · Cited by 1,851 · see citing works

ATR: an essential regulator of genome integrity

Cimprich, K. A., & Cortez, D. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2450 · Cited by 1,798 · see citing works

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

Olaussen, K. A., Dunant, A., Fouret, P. J., Brambilla, E. M., André, F., Haddad, V., Clermont, E., Filipits, M., Pirker, R., Popper, H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,725 · see citing works

-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin

Kinner, A., Wu, W., Staudt, C., & Iliakis, G. E. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn550 · Cited by 1,249 · see citing works

Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress

Ward, I. M., & Chen, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100569200 · Cited by 1,150 · see citing works

ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks

Jazayeri, A., Falck, J., Lukas, C., Bartek, J., Smith, G. C. M., Lukas, J., & Jackson, S. P. (2006) · Nature Cell Biology · doi:10.1038/ncb1337 · Cited by 1,064 · see citing works

ATM and DNA-PK Function Redundantly to Phosphorylate H2AX after Exposure to Ionizing Radiation

Stiff, T., O’Driscoll, M., Rief, N., Iwabuchi, K., Löbrich, M., & Jeggo, P. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3207 · Cited by 1,010 · see citing works

ATR and ATRIP: Partners in Checkpoint Signaling

Cortez, D., Guntuku, S., Qin, J., & Elledge, S. J. (2001) · Science · doi:10.1126/science.1065521 · Cited by 985 · see citing works

Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins

Wang, W. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2159 · Cited by 663 · see citing works

The combined status of ATM and p53 link tumor development with therapeutic responsePreprint

Jiang, H., Reinhardt, H. C., Bártková, J., Tommiska, J., BLOMQVIST, C. P., Nevanlinna, H. A., Bártek, J., Yaffe, M. B., & Hemann, M. T. (2009) · Genes & Development · doi:10.1101/gad.1815309 · Cited by 303 · see citing works

ATR inhibition selectively sensitizes G ₁ checkpoint-deficient cells to lethal premature chromatin condensation

Nghiem, P., Park, P. K., Kim, Y.-S., Vaziri, C., & Schreiber, S. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161281798 · Cited by 290 · see citing works

Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents

Charrier, J., Durrant, S. J., Golec, J. M. C., Kay, D. P., Knegtel, R. M. A., MacCormick, S., Mortimore, M., O'Donnell, M. E., Pinder, J. L., Reaper, P. M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101488z · Cited by 260 · see citing works

The Chk2 protein kinase

Ahn, J., Urist, M. J., & Prives, C. L. (2004) · DNA repair · doi:10.1016/j.dnarep.2004.03.033 · Cited by 240 · see citing works

Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer.Preprint

Oliver, T., Mercer, K. L., Sayles, L., Burke, J., Mendus, D., Lovejoy, K. S., Cheng, M., Subramanian, A., Mu, D., Powers, S., et al. (2010) · Genes & Development · doi:10.1101/gad.1897010 · Cited by 220 · see citing works

How do real tumors become resistant to cisplatin?

Borst, P., Rottenberg, S., & Jonkers, J. (2008) · Cell Cycle · doi:10.4161/cc.7.10.5930 · Cited by 192 · see citing works

Defective Mre11-dependent Activation of Chk2 by Ataxia Telangiectasia Mutated in Colorectal Carcinoma Cells in Response to Replication-dependent DNA Double Strand Breaks

Takemura, H., Rao, V. A., Sordet, O., Furuta, T., Miao, Z., Meng, L., Zhang, H., & Pommier, Y. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603747200 · Cited by 107 · see citing works

ATR Is Not Required for p53 Activation but Synergizes with p53 in the Replication Checkpoint

Nghiem, P., Park, P. K., Kim, Y.-S., Desai, B. N., & Schreiber, S. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106113200 · Cited by 98 · see citing works

Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line

Kim, W.-J., Vo, Q. N., Shrivastav, M., Lataxes, T. A., & Brown, K. D. (2002) · Oncogene · doi:10.1038/sj.onc.1205485 · Cited by 94 · see citing works

The ATR-mediated S phase checkpoint prevents rereplication in mammalian cells when licensing control is disrupted

Liu, E., Lee, A. Y., Chiba, T., Olson, E. E., Sun, P., & Wu, X. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200704138 · Cited by 70 · see citing works

Loss of ataxia telangiectasia mutated– and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival

Wilsker, D. F., & Bunz, F. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0679 · Cited by 57 · see citing works

The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms

Bolt, J., Vo, Q. N., Kim, W.-J., McWhorter, A. J., Thomson, J. L., Hagensee, M. E., Friedlander, P. L., Brown, K. D., & Gilbert, J. (2005) · Oral Oncology · doi:10.1016/j.oraloncology.2005.06.003 · Cited by 52 · see citing works

ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response

Blackford, A. N., & Jackson, S. P. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.05.015 · Cited by 1,953 · see citing works

DNA Damage Sensing by the ATM and ATR Kinases

Marechal, A., & Zou, L. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012716 · Cited by 1,514 · see citing works

Targeting the DNA Damage Response in Cancer

O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,551 · see citing works

State-of-the-art strategies for targeting the DNA damage response in cancer

Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189 · see citing works

Replication stress and cancer

Gaillard, H., García‐Muse, T., & Aguilera, A. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3916 · Cited by 1,076 · see citing works

DNA repair dysregulation from cancer driver to therapeutic target

Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051 · see citing works

Targeting DNA damage response pathways in cancer

Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N., & Tarsounas, M. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00535-5 · Cited by 868 · see citing works

ATM and ATR as therapeutic targets in cancer

Weber, A. M., & Ryan, A. J. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 644 · see citing works

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors

Brown, J. S., O’Carrigan, B., Jackson, S. P., & Yap, T. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 623 · see citing works

Targeting mutant p53 for cancer therapy: direct and indirect strategies

Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., Shen, J., Cai, L., Cai, X., & Chen, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01169-0 · Cited by 557 · see citing works

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors

Flynn, R. L., Cox, K. E., Jeitany, M., Wakimoto, H., Bryll, A. R., Ganem, N. J., Bersani, F., Pineda, J. R., Suvà, M. L., Benes, C. H., et al. (2015) · Science · doi:10.1126/science.1257216 · Cited by 504 · see citing works

Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors

Lord, C. J., Tutt, A. N. J., & Ashworth, A. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-050913-022545 · Cited by 476 · see citing works

ATM Mutations in Cancer: Therapeutic Implications

Choi, M. P., Kipps, T. J., & Kurzrock, R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0945 · Cited by 456 · see citing works

ATR phosphorylates SMARCAL1 to prevent replication fork collapsePreprint

Couch, F. B., Bansbach, C. E., Driscoll, R., Luzwick, J. W., Glick, G. G., Betous, R., Carroll, C. M., Jung, S. Y., Qin, J., Cimprich, K. A., et al. (2013) · Genes & Development · doi:10.1101/gad.214080.113 · Cited by 409 · see citing works

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

Williamson, C. T., Miller, R., Pemberton, H. N., Jones, S. E., Campbell, J., Konde, A., Badham, N., Rafiq, R., Brough, R., Gulati, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13837 · Cited by 382 · see citing works

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cellsPreprint

Yazinski, S. A., Comaills, V., Buisson, R., Genois, M., Nguyen, H. D., Ho, C. K., Kwan, T. T., Morris, R. T., Lauffer, S., Nussenzweig, A., et al. (2017) · Genes & Development · doi:10.1101/gad.290957.116 · Cited by 393 · see citing works

RAD52 Facilitates Mitotic DNA Synthesis Following Replication Stress

Bhowmick, R., Minocherhomji, S., & Hickson, I. D. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.10.037 · Cited by 388 · see citing works

The Replication Checkpoint Prevents Two Types of Fork Collapse without Regulating Replisome Stability

Dungrawala, H., Rose, K. L., Bhat, K. P., Mohni, K. N., Glick, G. G., Couch, F. B., & Cortez, D. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.030 · Cited by 376 · see citing works

Targeting replication stress in cancer therapy

da Costa, A. A. B. A., Chowdhury, D., Shapiro, G. I., D’Andrea, A. D., & Konstantinopoulos, P. A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00558-5 · Cited by 380 · see citing works

ATR/CHK1 inhibitors and cancer therapy

Qiu, Z., Oleinick, N. L., & Zhang, J. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.09.043 · Cited by 378 · see citing works

Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation

Fokas, E., Prevo, R., Pollard, J. R., Reaper, P. M., Charlton, P., Cornelissen, B. T., Vallis, K. A., Hammond, E. M., Olcina, M. M., McKenna, W. G., et al. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.181 · Cited by 372 · see citing works

Targeting ATR in cancer

Lecona, E., & Fernández-Capetillo, Ó. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0034-3 · Cited by 327 · see citing works

DNA damage checkpoint kinases in cancer

Smith, H. L., Southgate, H. E. D., Tweddle, D. A., & Curtin, N. J. (2020) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2020.3 · Cited by 323 · see citing works

Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase

Buisson, R., Boisvert, J. L., Benes, C. H., & Zou, L. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.029 · Cited by 316 · see citing works

Exploiting replicative stress to treat cancer

Dobbelstein, M., & Sørensen, C. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4553 · Cited by 300 · see citing works

Polyubiquitinated PCNA Recruits the ZRANB3 Translocase to Maintain Genomic Integrity after Replication Stress

Ciccia, A., Nimonkar, A. V., Hu, Y., Hajdú, I., Achar, Y. J., Izhar, L., Petit, S. A., Adamson, B., Yoon, J. C., Kowalczykowski, S. C., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.05.024 · Cited by 293 · see citing works

Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models

Kim, H., George, E. M., Ragland, R. L., Rafail, S., Zhang, R., Krepler, C., Morgan, M. A., Herlyn, M., Brown, E. J., & Simpkins, F. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2273 · Cited by 294 · see citing works

ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells

Kwok, M., Davies, N., Agathanggelou, A., Smith, E., Oldreive, C., Petermann, E., Stewart, G. S., Brown, J., Lau, A., Pratt, G., et al. (2015) · Blood · doi:10.1182/blood-2015-05-644872 · Cited by 281 · see citing works

DNA Damage Response: Three Levels of DNA Repair Regulation

Sirbu, B. M., & Cortez, D. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012724 · Cited by 272 · see citing works

Molecular Pathways: Targeting ATR in Cancer Therapy

Karnitz, L. M., & Zou, L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0479 · Cited by 267 · see citing works

PRIMPOL-Mediated Adaptive Response Suppresses Replication Fork Reversal in BRCA-Deficient Cells

Quinet, A., Tirman, S., Jackson, J., Šviković, S., Lemacon, D. S., Carvajal-Maldonado, D., González‐Acosta, D., Vessoni, A. T., Cybulla, E., Wood, M. D., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.10.008 · Cited by 259 · see citing works

The Colibactin Genotoxin Generates DNA Interstrand Cross-Links in Infected Cells

Bossuet‐Greif, N., Vignard, J., Taieb, F. E., Mirey, G., Dubois, D., Petit, C. R., Oswald, É., & Nougayrède, J. (2018) · mBio · doi:10.1128/mbio.02393-17 · Cited by 260 · see citing works

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

Yap, T. A., O’Carrigan, B., Penney, M. S., Lim, J. S. J., Brown, J. S., Miguel, M. J. D., Tunariu, N., Pérez-López, R., Rodrigues, D. N., Riisnaes, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02404 · Cited by 252 · see citing works

Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways

Morgan, M. A., & Lawrence, T. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3229 · Cited by 252 · see citing works

PRP19 Transforms into a Sensor of RPA-ssDNA after DNA Damage and Drives ATR Activation via a Ubiquitin-Mediated Circuitry

Maréchal, A., Li, J.-M., Ji, X. Y., Wu, C.-S. P., Yazinski, S. A., Nguyen, H. D., Liu, S., Jiménez, A. E., Jin, J., & Zou, L. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.11.002 · Cited by 246 · see citing works

Identification of Proteins at Active, Stalled, and Collapsed Replication Forks Using Isolation of Proteins on Nascent DNA (iPOND) Coupled with Mass Spectrometry

Sirbu, B. M., McDonald, W. H., Dungrawala, H., Badu-Nkansah, A., Kavanaugh, G. M., Chen, Y., Tabb, D. L., & Cortez, D. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.511337 · Cited by 246 · see citing works

The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy

Prevo, R., Fokas, E., Reaper, P. M., Charlton, P., Pollard, J. R., McKenna, W. G., Muschel, R. J., & Brunner, T. B. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21093 · Cited by 242 · see citing works

The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancerin vivo

Vendetti, F. P., Lau, A., Schamus, S., Conrads, T. P., O’Connor, M. J., & Bakkenist, C. J. (2015) · Oncotarget · doi:10.18632/oncotarget.6247 · Cited by 241 · see citing works

Targeting the ATR-CHK1 Axis in Cancer Therapy

Rundle, S., Bradbury, A., Drew, Y., & Curtin, N. J. (2017) · Cancers · doi:10.3390/cancers9050041 · Cited by 235 · see citing works

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

Konstantinopoulos, P. A., Cheng, S., Hendrickson, A. E. W., Penson, R. T., Schumer, S., Doyle, L. A., Lee, E. K., Kohn, E. C., Duska, L., Crispens, M. A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30180-7 · Cited by 226 · see citing works

The Meaning, Measurement and Modification of Hypoxia in the Laboratory and the Clinic

Hammond, E. M., Asselin, M., Forster, D. M., O’Connor, J. P. B., Senra, J. M., & Williams, K. J. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.02.002 · Cited by 217 · see citing works

Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro

Patel, A. G., Lorenzo, S. B. D., Flatten, K. S., Poirier, G. G., & Kaufmann, S. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2890 · Cited by 212 · see citing works

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

Wengner, A. M., Siemeister, G., Lücking, U., Lefranc, J., Wortmann, L., Lienau, P., Bader, B., Bömer, U., Moosmayer, D., Eberspächer, U., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0019 · Cited by 211 · see citing works

ATM signalling and cancer

Cremona, C. A., & Behrens, A. (2013) · Oncogene · doi:10.1038/onc.2013.275 · Cited by 206 · see citing works

ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status

Huntoon, C. J., Flatten, K. S., Hendrickson, A. E. W., Huehls, A. M., Sutor, S. L., Kaufmann, S. H., & Karnitz, L. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0110 · Cited by 205 · see citing works

A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors

Ruiz, S., Mayor‐Ruiz, C., Lafarga, V., Murga, M., Vega-Sendino, M., Ortega, S., & Fernández-Capetillo, Ó. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.03.006 · Cited by 194 · see citing works

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

Hall, A. B., Newsome, D., Wang, Y., Boucher, D. M., Eustace, B. K., Gu, Y., Hare, B. J., Johnson, M., Li, H. Y., Milton, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2158 · Cited by 200 · see citing works

ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation

Vendetti, F. P., Karukonda, P., Clump, D. A., Teo, T., Lalonde, R., Nugent, K., Ballew, M., Kiesel, B. F., Beumer, J. H., Sarkar, S. N., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96519 · Cited by 198 · see citing works

Translating p53-based therapies for cancer into the clinic

Peuget, S., Zhou, X., & Selivanova, G. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-023-00658-3 · Cited by 198 · see citing works

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

Peasland, A., Wang, L.-Z., Rowling, E. J., Kyle, S., Chen, T., Hopkins, A. P., Cliby, W. A., Sarkaria, J. N., Beale, G., Edmondson, R. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.243 · Cited by 197 · see citing works

Targeting ATR in DNA damage response and cancer therapeutics

Fokas, E., Prevo, R., Hammond, E. M., Brunner, T. B., McKenna, W. G., & Muschel, R. J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.03.002 · Cited by 192 · see citing works

Aneuploidy generates proteotoxic stress and DNA damage concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells

Ohashi, A., Ohori, M., Iwai, K., Nakayama, Y., Nambu, T., Morishita, D., Kawamoto, T., Miyamoto, M., Hirayama, T., Okaniwa, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms8668 · Cited by 192 · see citing works

Coupling of Homologous Recombination and the Checkpoint by ATR

Buisson, R., Joshi, N., Rodrigue, A., Ho, C. K., Kreuzer, J., Foo, T. K., Hardy, É. J.-L., Dellaire, G., Haas, W., Xia, B., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.12.007 · Cited by 181 · see citing works

Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR

Schoppy, D. W., Ragland, R. L., Gilad, O., Shastri, N., Peters, A. A., Murga, M., Fernández-Capetillo, Ó., Diehl, J. A., & Brown, E. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58928 · Cited by 180 · see citing works

Replication Stress Drives Constitutive Activation of the DNA Damage Response and Radioresistance in Glioblastoma Stem-like Cells

Carruthers, R., Ahmed, S. U., Ramachandran, S., Strathdee, K. E., Kurian, K. M., Hedley, A., Gomez-Roman, N., Kalna, G., Neilson, M., Gilmour, L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0569 · Cited by 180 · see citing works

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells

Lloyd, R. L., Wijnhoven, P. W. G., Ramos‐Montoya, A., Wilson, Z., Illuzzi, G., Falenta, K., Jones, G. N., James, N. H., Chabbert, C. D., Stott, J., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1328-y · Cited by 181 · see citing works

The DNA Damaging Revolution: PARP Inhibitors and Beyond

Yap, T. A., Plummer, R., Azad, N. S., & Helleday, T. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238473 · Cited by 175 · see citing works

Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs

Toledo, L. I., Murga, M., & Fernández-Capetillo, Ó. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.002 · Cited by 174 · see citing works

Functions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway

Yazinski, S. A., & Zou, L. (2016) · Annual Review of Genetics · doi:10.1146/annurev-genet-121415-121658 · Cited by 173 · see citing works

ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses

Jossé, R., Martin, S. E., Guha, R., Ormanoglu, P., Pfister, T. D., Reaper, P. M., Barnes, C. S., Jones, J. L., Charlton, P., Pollard, J. R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3369 · Cited by 176 · see citing works

Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?

Bradbury, A., Hall, S., Curtin, N. J., & Drew, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107450 · Cited by 176 · see citing works

PARP inhibitors: enhancing efficacy through rational combinations

Bhamidipati, D., Haro-Silerio, J. I., Yap, T. A., & Ngoi, N. Y. L. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02326-7 · Cited by 179 · see citing works

Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors

Thomas, A., Redon, C. E., Sciuto, L. C., Padiernos, E., Ji, J. J., Lee, M.-J., Yuno, A., Lee, S., Zhang, Y., Tran, L. T.-N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.6915 · Cited by 173 · see citing works

G-Quadruplex DNA as a Molecular Target for Induced Synthetic Lethality in Cancer Cells

McLuckie, K. I. E., Antonio, M. D., Zecchini, H. I., Xian, J., Caldas, C., Krippendorff, B., Tannahill, D., Lowe, C., & Balasubramanian, S. (2013) · Journal of the American Chemical Society · doi:10.1021/ja404868t · Cited by 172 · see citing works

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition

Pires, I. M., Olcina, M. M., Anbalagan, S., Pollard, J. R., Reaper, P. M., Charlton, P., McKenna, W. G., & Hammond, E. M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.265 · Cited by 171 · see citing works

DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy

Carrassa, L., & Damia, G. L. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.013 · Cited by 170 · see citing works

Targeting the S and G2 checkpoint to treat cancer

Chen, T., Stephens, P., Middleton, F. K., & Curtin, N. J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.009 · Cited by 168 · see citing works

Phosphatidylinositol 3-Kinase (PI3K) and Phosphatidylinositol 3-Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring

Andrš, M., Korábečný, J., Jun, D., Hodný, Z., Bártek, J., & Kuča, K. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501026z · Cited by 162 · see citing works

Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development

Dreyer, S. B., Chang, D. K.-F., Bailey, P. J., & Biankin, A. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2411 · Cited by 160 · see citing works

Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes

Nguyen, H. D., Leong, W. Y., Li, W., Reddy, P. N. G., Sullivan, J. D., Walter, M. J., Zou, L., & Graubert, T. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3970 · Cited by 162 · see citing works

ATR-Mediated Phosphorylation of FANCI Regulates Dormant Origin Firing in Response to Replication Stress

Chen, Y.-H., Jones, M. V., Yin, Y., Crist, S. B., Colnaghi, L., Sims, R. J., Rothenberg, E., Jallepalli, P. V., & Huang, T. T. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.02.031 · Cited by 158 · see citing works

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib

Wilson, Z., Odedra, R., Wallez, Y., Wijnhoven, P. W. G., Hughes, A. M., Gerrard, J., Jones, G. N., Bargh-Dawson, H., Brown, E., Young, L. A., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2997 · Cited by 160 · see citing works

Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations

Marshall, C. H., Sokolova, A. O., McNatty, A. L., Cheng, H. H., Eisenberger, M. A., Bryce, A. H., Schweizer, M. T., & Antonarakis, E. S. (2019) · European Urology · doi:10.1016/j.eururo.2019.02.002 · Cited by 158 · see citing works

Targeting the replication stress response in cancer

Forment, J. V., & O’Connor, M. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.005 · Cited by 159 · see citing works

Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand

Mei, L., Zhang, J., He, K., & Zhang, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0733-6 · Cited by 157 · see citing works

AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells

Min, A., Im, S., Jang, H., Kim, S., Lee, M., Kim, D. K., Yang, Y., Kim, H. J., Lee, K.-H., Kim, J. W., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0378 · Cited by 155 · see citing works

Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy

Manic, G., Obrist, F., Sistigu, A., & Vitale, I. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1012976 · Cited by 147 · see citing works

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities

Sanjiv, K., Hagenkort, A., Calderón‐Montaño, J. M., Koolmeister, T., Reaper, P. M., Mortusewicz, O., Jacques, S. A., Kuiper, R., Schultz, N., Scobie, M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.12.032 · Cited by 147 · see citing works

Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

Stover, E. H., Konstantinopoulos, P. A., Matulonis, U. A., & Swisher, E. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0247 · Cited by 146 · see citing works

Linking hypoxia, DNA damage and proliferation in multicellular tumor spheroids

Riffle, S., Pandey, R. N., Albert, M., & Hegde, R. S. (2017) · BMC Cancer · doi:10.1186/s12885-017-3319-0 · Cited by 142 · see citing works

ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency

Mohni, K. N., Kavanaugh, G. M., & Cortez, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3229 · Cited by 141 · see citing works

Drug discovery in advanced prostate cancer: translating biology into therapy

Yap, T. A., Smith, A. D., Ferraldeschi, R., Al‐Lazikani, B., Workman, P., & Bono, J. S. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.120 · Cited by 141 · see citing works

Targeting DNA damage repair in small cell lung cancer and the biomarker landscape

Sen, T., Gay, C. M., & Byers, L. A. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.02.03 · Cited by 137 · see citing works

Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies

Minchom, A. R., Aversa, C., & Lopez, J. S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918786658 · Cited by 137 · see citing works

Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition

Wang, C., Wang, G., Feng, X., Shepherd, P. D. A., Zhang, J., Tang, M., Chen, Z., Srivastava, M., McLaughlin, M. E., Navone, N. M., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0606-4 · Cited by 137 · see citing works

Two Distinct Modes of ATR Activation Orchestrated by Rad17 and Nbs1

Shiotani, B., Nguyen, H. D., Håkansson, P., Maréchal, A., Tse, A., Tahara, H., & Zou, L. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.018 · Cited by 137 · see citing works

Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis

Bukhari, A. B., Lewis, C. W., Pearce, J. J., Luong, D., Chan, G. K. T., & Gamper, A. M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122622 · Cited by 138 · see citing works

Human papillomavirus E6 and E7: What remains?

Vats, A., Trejo-Cerro, Ó., Thomas, M., & Banks, L. (2021) · Tumour Virus Research · doi:10.1016/j.tvr.2021.200213 · Cited by 136 · see citing works

CDK4/6 inhibitors induce replication stress to cause long‐term cell cycle withdrawal

Crozier, L., Foy, R., Mouery, B. L., Whitaker, R. H., Corno, A., Spanos, C., Ly, T., Cook, J. G., & Saurin, A. T. (2022) · The EMBO Journal · doi:10.15252/embj.2021108599 · Cited by 141 · see citing works

Replication stress and cancer: It takes two to tango

Lecona, E., & Fernández-Capetillo, Ó. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.09.019 · Cited by 131 · see citing works

Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions

Basourakos, S. P., Li, L., Aparicio, A. M., Corn, P. G., Kim, J., & Thompson, T. C. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666161214114948 · Cited by 133 · see citing works

Targeting DNA repair pathway in cancer: Mechanisms and clinical application

Wang, M., Chen, S., & Ao, D. (2021) · MedComm · doi:10.1002/mco2.103 · Cited by 134 · see citing works

Progress towards a clinically-successful ATR inhibitor for cancer therapy

Barnieh, F. M., Loadman, P. M., & Falconer, R. A. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100017 · Cited by 130 · see citing works

APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition

Buisson, R., Lawrence, M. S., Benes, C. H., & Zou, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3389 · Cited by 124 · see citing works

Exploiting DNA repair defects in colorectal cancer

Reilly, N. M., Novara, L., Nicolantonio, F. D., & Bardelli, A. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12467 · Cited by 129 · see citing works

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours

Middleton, M. R., Dean, E. J., Evans, T. R. J., Shapiro, G. I., Pollard, J. R., Hendriks, B. S., Falk, M., Díaz-Padilla, I., & Plummer, R. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01405-x · Cited by 126 · see citing works

MRN, CtIP, and BRCA1 mediate repair of topoisomerase II–DNA adducts

Aparicio, T., Baer, R. J., Gottesman, M. E., & Gautier, J. (2016) · The Journal of Cell Biology · doi:10.1083/jcb.201504005 · Cited by 123 · see citing works

ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells

Ronco, C., Martin, A. R., Demange, L., & Benhida, R. (2016) · MedChemComm · doi:10.1039/c6md00439c · Cited by 122 · see citing works

Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors

Tomicic, M. T., & Kaina, B. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.09.002 · Cited by 121 · see citing works

Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy

Górecki, L., Andrš, M., Řezáčová, M., & Korábečný, J. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107518 · Cited by 120 · see citing works

Abstract 3235: Development of potent and selective inhibitors for ATR: An adjuvant for DNA damage based chemotherapeutics

Kirubakaran, S., Thiruvenkatam, V., & Shaik, A. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-3235

ATM and ATR as therapeutic targets in cancer

Weber, A. M., & Ryan, A. J. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 644 · see citing works

Small Molecules Targeting Ataxia Telangiectasia and Rad3-Related (ATR) Kinase: An Emerging way to Enhance Existing Cancer Therapy

Andrš, M., Korábečný, J., Nepovimová, E., Jun, D., Hodný, Z., & Kuča, K. (2016) · Current Cancer Drug Targets · doi:10.2174/156800961603160206122927 · Cited by 12 · see citing works

Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents

Charrier, J., Durrant, S. J., Golec, J. M. C., Kay, D. P., Knegtel, R. M. A., MacCormick, S., Mortimore, M., O'Donnell, M. E., Pinder, J. L., Reaper, P. M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101488z · Cited by 260 · see citing works

Abstract 6212: Inhibition of ATM-dependent checkpoint control and DNA double-strand break repair enhances the efficacy of ATR inhibitors

Turchick, A., Zimmermann, A., Chiu, L.-Y., Dahmen, H., Elenbaas, B., Zenke, F. T., Blaukat, A., & Vassilev, L. T. (2023) · Cancer Research · doi:10.1158/1538-7445.am2023-6212